BUFFALO, N.Y. — Harvey Arbesman, MD, clinical assistant professor of dermatology and social and preventive medicine at the University at Buffalo, has been named one of 12 “Top Solvers” for 2009 by InnoCentive Inc., an organization that sponsors international challenges to provide innovative solutions to complex problems.
Arbesman developed a promising biomarker to assess disease progression of amyotrophic lateral sclerosis, or ALS.
The “Top Solvers” were awarded the most prize dollars and solved extraordinarily complex challenges. This year’s winners came from six countries, the majority from the United States. The InnoCentive Solver community comprises more than 200,000 scientists, engineers, business people, academics and researchers who are striving to answer issues of global concern to persons worldwide.
Arbesman maintains an active dermatology practice and is founder and vice president of ArbesIdeas, a life sciences-related research and consulting company. One of the company’s goals is to promote creative thinking in developing medical hypotheses.
“Sometimes you need a new theory to generate a new therapy or simply to understand disease in general,” says Arbesman. “Such hypotheses are what really create leaps in our understanding of critical problems.”